Staffan Hägg
Staffan Hägg
Verifierad e-postadress på liu.se
Citeras av
Citeras av
Incidence of fatal adverse drug reactions: a population based study
K Wester, AK Jönsson, O Spigset, H Druid, S Hägg
British journal of clinical pharmacology 65 (4), 573-579, 2008
Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions–a meta-analysis
KM Hakkarainen, K Hedna, M Petzold, S Hägg
PloS one 7 (3), e33236, 2012
Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
S Hagg, L Joelsson, T Mjorndal, O Spigset, G Oja, R Dahlqvist
Journal of Clinical Psychiatry 59 (6), 294-299, 1998
Adverse drug reactions as a cause for admissions to a department of internal medicine
T Mjörndal, MD Boman, S Hägg, M Bäckström, BE Wiholm, A Wahlin, ...
Pharmacoepidemiology and drug safety 11 (1), 65-72, 2002
High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia
S Hägg, Y Lindblom, T Mjörndal, R Adolfsson
International clinical psychopharmacology 21 (2), 93-98, 2006
Association of venous thromboembolism and clozapine
S Hägg, O Spigset, TG Söderström
The Lancet 355 (9210), 1155-1156, 2000
Glucose intolerance with atypical antipsychotics
K Hedenmalm, S Hägg, M Ståhl, Ö Mortimer, O Spigset
Drug safety 25, 1107-1116, 2002
Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers
S Hägg, O Spigset, R Dahlqvist
British journal of clinical pharmacology 51 (2), 169-173, 2001
Myocarditis related to clozapine treatment
S Hägg, O Spigset, AB BAHons, TG Söderström
Journal of clinical psychopharmacology 21 (4), 382-388, 2001
Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study
K Hedna, KM Hakkarainen, H Gyllensten, AK Jönsson, M Petzold, S Hägg
European journal of clinical pharmacology 71, 1525-1533, 2015
Antipsychotic-induced venous thromboembolism: a review of the evidence
S Hägg, O Spigset
CNS drugs 16, 765-776, 2002
Analgesics and breast-feeding: safety considerations
O Spigset, S Hägg
Paediatric drugs 2, 223-238, 2000
Fatal unintentional intoxications with tramadol during 1995–2005
M Tjäderborn, AK Jönsson, S Hägg, J Ahlner
Forensic science international 173 (2-3), 107-111, 2007
Excretion of paroxetine into breast milk
R Ohman, S Hagg, L Carleborg, O Spigset
Journal of Clinical Psychiatry 60 (8), 519-523, 1999
Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics
S Hagg, S Soderberg, B Ahren, T Olsson, T Mjorndal
Journal of Clinical Psychiatry 62 (11), 843-848, 2001
Drug‐induced torsades de pointes: a review of the Swedish pharmacovigilance database
C Åström‐Lilja, JM Odeberg, E Ekman, S Hägg
Pharmacoepidemiology and drug safety 17 (6), 587-592, 2008
Risk of venous thromboembolism due to antipsychotic drug therapy
S Hägg, AK Jönsson, O Spigset
Expert opinion on drug safety 8 (5), 537-547, 2009
Prevalence, nature and potential preventability of adverse drug events–a population‐based medical record study of 4970 adults
KM Hakkarainen, H Gyllensten, AK Jönsson, K Andersson Sundell, ...
British journal of clinical pharmacology 78 (1), 170-183, 2014
Effect of caffeine on clozapine pharmacokinetics in healthy volunteers
S Hägg, O Spigset, T Mjörndal, R Dahlqvist
British journal of clinical pharmacology 49 (1), 59-63, 2000
Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden
I Jacobsson, AK Jönsson, B Gerdén, S Hägg
Pharmacoepidemiology and drug safety 18 (11), 1039-1047, 2009
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20